中华核医学与分子影像杂志
中華覈醫學與分子影像雜誌
중화핵의학여분자영상잡지
Chinese Journal of Nuclear Medicine and Molecular Imaging
2012年
1期
42-45
,共4页
眶肿瘤%近距离放射疗法%碘放射性同位素%放射治疗计划,计算机辅助
眶腫瘤%近距離放射療法%碘放射性同位素%放射治療計劃,計算機輔助
광종류%근거리방사요법%전방사성동위소%방사치료계화,계산궤보조
Orbital neoplasms%Brachytherapy%Iodine radioisotopes%Radiotherapy planning,computer-assissted
目的 探讨术前TPS及术后质量验证在125I粒子近距离治疗眼眶肿瘤中的作用.方法 对2005年4月至2009年12月期间66例行125I粒子近距离治疗的眼眶肿瘤患者资料进行回顾性分析.66例中43例有数字影像资料者术前应用TPS,处方剂量140 Gy;余23例患者未行术前TPS,术中按间隔1 cm原则平行排列粒子.对所有66例患者术后均应用TPS进行质量验证.术后3、6、12和24个月分别对患者进行CT和(或)MRI随访.采用SPSS 17.0软件进行x2检验及Kaplan-Meier法log-rank 检验.结果 66例患者共植入125I粒子1070粒,平均(16.2±7.3)粒/人.TPS术前计划组及未计划组术后质量验证满意率分别为79.07％( 34/43)及43.48％( 10/23),差异有统计学意义(x2=8.542,P=0.003).10例患者术后失访,仅有术后验证资料,无影像学随访资料.TPS质量验证满意组术后3、6、12和24个月肿瘤局部复发率分别为0(0/37)、6.25％ (2/32)、13.64％ (3/22)和3/9,TPS质量验证不满意组局部复发率分别为5.26％ (1/19)、16.67％ (3/18)、30.77％ (4/13)和6/6,2组间差异有统计学意义(x2=9.017,P=0.0003).结论 TPS在125I粒子近距离治疗眼眶肿瘤中起重要作用.术前TPS是治疗成功的前提,TPS术后质量验证能较好地预测治疗效果,并指导临床确定进一步治疗方案.
目的 探討術前TPS及術後質量驗證在125I粒子近距離治療眼眶腫瘤中的作用.方法 對2005年4月至2009年12月期間66例行125I粒子近距離治療的眼眶腫瘤患者資料進行迴顧性分析.66例中43例有數字影像資料者術前應用TPS,處方劑量140 Gy;餘23例患者未行術前TPS,術中按間隔1 cm原則平行排列粒子.對所有66例患者術後均應用TPS進行質量驗證.術後3、6、12和24箇月分彆對患者進行CT和(或)MRI隨訪.採用SPSS 17.0軟件進行x2檢驗及Kaplan-Meier法log-rank 檢驗.結果 66例患者共植入125I粒子1070粒,平均(16.2±7.3)粒/人.TPS術前計劃組及未計劃組術後質量驗證滿意率分彆為79.07％( 34/43)及43.48％( 10/23),差異有統計學意義(x2=8.542,P=0.003).10例患者術後失訪,僅有術後驗證資料,無影像學隨訪資料.TPS質量驗證滿意組術後3、6、12和24箇月腫瘤跼部複髮率分彆為0(0/37)、6.25％ (2/32)、13.64％ (3/22)和3/9,TPS質量驗證不滿意組跼部複髮率分彆為5.26％ (1/19)、16.67％ (3/18)、30.77％ (4/13)和6/6,2組間差異有統計學意義(x2=9.017,P=0.0003).結論 TPS在125I粒子近距離治療眼眶腫瘤中起重要作用.術前TPS是治療成功的前提,TPS術後質量驗證能較好地預測治療效果,併指導臨床確定進一步治療方案.
목적 탐토술전TPS급술후질량험증재125I입자근거리치료안광종류중적작용.방법 대2005년4월지2009년12월기간66례행125I입자근거리치료적안광종류환자자료진행회고성분석.66례중43례유수자영상자료자술전응용TPS,처방제량140 Gy;여23례환자미행술전TPS,술중안간격1 cm원칙평행배렬입자.대소유66례환자술후균응용TPS진행질량험증.술후3、6、12화24개월분별대환자진행CT화(혹)MRI수방.채용SPSS 17.0연건진행x2검험급Kaplan-Meier법log-rank 검험.결과 66례환자공식입125I입자1070립,평균(16.2±7.3)립/인.TPS술전계화조급미계화조술후질량험증만의솔분별위79.07％( 34/43)급43.48％( 10/23),차이유통계학의의(x2=8.542,P=0.003).10례환자술후실방,부유술후험증자료,무영상학수방자료.TPS질량험증만의조술후3、6、12화24개월종류국부복발솔분별위0(0/37)、6.25％ (2/32)、13.64％ (3/22)화3/9,TPS질량험증불만의조국부복발솔분별위5.26％ (1/19)、16.67％ (3/18)、30.77％ (4/13)화6/6,2조간차이유통계학의의(x2=9.017,P=0.0003).결론 TPS재125I입자근거리치료안광종류중기중요작용.술전TPS시치료성공적전제,TPS술후질량험증능교호지예측치료효과,병지도림상학정진일보치료방안.
Objective To investigate the role of TPS in 125I brachytherapy for orbital tumors.Methods Sixty-six patients with orbital tumor treated with 125I seeds from 2005 to 2009 were retrospectively analyzed.Forty-three patients were treated using TPS guided brachytherapy and the prescribed dose was 140 Gy.Other 23 patients were treated without TPS but simply implanted with 125I seeds at 1 cm intervals in parallelwith each other intraoperatively.CT and TPS quality verification were performed postoperatively in all patients.Also,CT and (or) MRI examination were performed at 3,6,12 and 24 months after brachytherapy for follow-up.x2 test and Kaplan-Meier survival analysis with log-rank significance test were used with SPSS 17.0.Results A total of 1070 125 I seeds were implanted in 66 cases,on average,( 16.2 ± 7.3) seeds for each patient.The satisfaction rates of postoperative quality verification in patients with and without TPS preplans were 79.07％ (34/43) and 43.48％ (10/23) respectively (x2 =8.542,P =0.003 ).Ten patients were lost in follow-up.Local recurrence rates in patients with favorable postoperative quality verification were 0(0/37) in 3 months,6.25％ (2/32) in 6 months,13.64％ (3/22) in 12 months and 3/9 in 24 months respectively,which were significantly different from those (5.26％ (1/19),16.67％ (3/18),30.77％ (4/13),6/6 )in the patients with inferior postoperative quality verification (x2 =9.017,P =0.0003).Conclusions TPS plays an important role in 125I brachytherapy for orbital tumors.Also,postoperative quality verification by TPS may help predict the local recurrence after brachytherapy.
